Jennison Associates
AMLX icon

Jennison Associates’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jennison Associates’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$644K Buy
+35,841
New +$554K ﹤0.01% 539
2025
Q4 		– Sell
-578,659
Closed -$7.86M – 583
2025
Q3 		$7.86M Buy
+578,659
New +$5.45M ﹤0.01% 386

Other funds holding AMLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
IGAM
iA Global Asset Management Quebec, Quebec, Canada $8.42B AUM 47.61% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Jennison Associates's AMLX Position: Q2 2026 in Review

Jennison Associates opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 35,841 shares worth $644K. The stake represents ﹤0.01% of the portfolio and ranks #539 among its holdings. This is a return to the name: Jennison Associates previously reported a position in AMLX as recently as Q3 2025.

Jennison Associates first reported a position in AMLX in Q3 2025 and has held it in 2 quarters since. The position peaked at $7.86M in Q3 2025. 52 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Jennison Associates held 35,841 shares of Amylyx Pharmaceuticals worth $644K as of Q2 2026.
  • Amylyx Pharmaceuticals was a new Jennison Associates position in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Jennison Associates's portfolio in Q2 2026, its #539 holding.
  • Jennison Associates first reported a position in Amylyx Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Jennison Associates's Amylyx Pharmaceuticals position peaked at $7.86M in Q3 2025.
  • 52 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.